Total Payments
$905,454
2024 Payments
$122,729
Companies
63
Transactions
1,518
Medicare Patients
1,803
Medicare Billing
$153,888
Payment Breakdown by Category
Other$662,194 (73.1%)
Travel$118,488 (13.1%)
Consulting$96,260 (10.6%)
Food & Beverage$28,076 (3.1%)
Education$435.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $644,894 | 187 | 71.2% |
| Travel and Lodging | $118,488 | 518 | 13.1% |
| Consulting Fee | $96,260 | 74 | 10.6% |
| Food and Beverage | $28,076 | 718 | 3.1% |
| Honoraria | $17,300 | 9 | 1.9% |
| Education | $435.93 | 12 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $392,541 | 472 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $306,421 | 370 | $0 (2024) |
| Lilly USA, LLC | $25,175 | 81 | $0 (2024) |
| Exelixis Inc. | $24,941 | 61 | $0 (2024) |
| PFIZER INC. | $24,434 | 73 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17,412 | 31 | $0 (2018) |
| GENZYME CORPORATION | $14,496 | 20 | $0 (2023) |
| Astellas Pharma US Inc | $12,879 | 32 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $12,839 | 14 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $10,538 | 34 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122,729 | 210 | E.R. Squibb & Sons, L.L.C. ($58,848) |
| 2023 | $85,521 | 109 | Daiichi Sankyo Inc. ($52,717) |
| 2022 | $101,824 | 100 | E.R. Squibb & Sons, L.L.C. ($47,201) |
| 2021 | $78,030 | 86 | Daiichi Sankyo Inc. ($42,906) |
| 2020 | $52,988 | 72 | Daiichi Sankyo Inc. ($21,888) |
| 2019 | $159,683 | 251 | Daiichi Sankyo Inc. ($59,254) |
| 2018 | $181,727 | 331 | Daiichi Sankyo Inc. ($76,639) |
| 2017 | $122,952 | 359 | Daiichi Sankyo Inc. ($55,459) |
All Payment Transactions
1,518 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Oncology | ||||||
| 12/16/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $14.59 | General |
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $974.57 | General |
| Category: Oncology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $69.67 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Oncology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,664.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,566.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $209.04 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.09 | General |
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.83 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $17.01 | General |
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | TIVDAK (Biological) | Travel and Lodging | In-kind items and services | $871.50 | General |
| Category: Oncology | ||||||
| 11/08/2024 | PFIZER INC. | TIVDAK (Biological) | Travel and Lodging | In-kind items and services | $454.29 | General |
| Category: Oncology | ||||||
| 11/08/2024 | PFIZER INC. | TIVDAK (Biological) | Travel and Lodging | In-kind items and services | $349.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $126.57 | General |
| Category: Oncology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $158.03 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $3.16 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: HORMONE THERAPY | ||||||
| 11/01/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 381 | 495 | $126,850 | $34,881 |
| 2022 | 8 | 440 | 543 | $126,964 | $37,578 |
| 2021 | 9 | 459 | 574 | $133,875 | $43,615 |
| 2020 | 12 | 523 | 576 | $114,792 | $37,814 |
Total Patients
1,803
Total Services
2,188
Medicare Billing
$153,888
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 103 | $29,395 | $6,824 | 23.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 62 | $20,312 | $5,666 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 86 | $14,706 | $5,485 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 95 | $18,048 | $4,013 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 27 | $11,364 | $2,962 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 43 | 53 | $6,254 | $2,467 | 39.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $9,452 | $2,279 | 24.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $6,659 | $1,913 | 28.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 18 | $7,020 | $1,737 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 15 | $3,640 | $1,536 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 98 | 124 | $33,379 | $8,286 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 77 | 114 | $20,071 | $7,613 | 37.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 53 | $15,634 | $4,194 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 36 | 36 | $9,360 | $3,799 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $10,511 | $3,137 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 59 | 60 | $11,469 | $2,867 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 65 | 70 | $8,339 | $2,511 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 20 | $8,430 | $2,279 | 27.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 15 | $5,645 | $1,574 | 27.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 11 | 11 | $1,859 | $713.68 | 38.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 11 | $2,267 | $604.40 | 26.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 77 | 118 | $20,178 | $8,745 | 43.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 105 | $28,201 | $7,673 | 27.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 71 | $20,448 | $5,576 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 96 | 105 | $11,861 | $5,036 | 42.5% |
About Dr. Alexander Barsouk, MD
Dr. Alexander Barsouk, MD is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114929544.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Barsouk, MD has received a total of $905,454 in payments from pharmaceutical and medical device companies, with $122,729 received in 2024. These payments were reported across 1,518 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($644,894).
As a Medicare-enrolled provider, Barsouk has provided services to 1,803 Medicare beneficiaries, totaling 2,188 services with total Medicare billing of $153,888. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 08/15/2005
- Last Updated 10/09/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114929544
Products in Payments
- INJECTAFER (Drug) $392,431
- OPDIVO (Biological) $242,403
- EMPLICITI (Biological) $50,385
- ERBITUX (Drug) $22,005
- GILOTRIF (Drug) $17,412
- ELITEK (Drug) $14,247
- XTANDI (Drug) $14,161
- Cabometyx (Drug) $13,671
- CABOMETYX (Drug) $11,270
- Aliqopa (Drug) $10,645
- CALQUENCE (Drug) $10,170
- BELEODAQ (Drug) $6,594
- Vonjo (Drug) $6,500
- IBRANCE (Drug) $6,225
- ADCETRIS (Biological) $4,865
- Monoferric (Drug) $4,328
- TECENTRIQ (Biological) $3,873
- Alecensa (Biological) $3,342
- MONOFERRIC (Drug) $3,026
- NINLARO (Drug) $2,932
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360
Ahmad Tarhini, Md, MD
Hematology & Oncology — Payments: $290,751
Hematology & Oncology $290,751